Autistics Children
Conditions
Keywords
Autism, Bumetanide, GABA, NKCC1
Brief summary
The purpose of this study is to determine if a treatment by bumetanide presents an efficiency at the level of the neuronal maturation in the autism
Interventions
DRUGbumetanide
Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
Sponsors
University Hospital, Brest
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
3 Years to 10 Years
Healthy volunteers
No
Inclusion criteria
* Children from 3 to 10 years old, answering the diagnosis of typical autism according to the diagnostic criteria of autism of the classification of the WHO ( CIM-10) and the parents of which gave a free, enlightened and written consent.
Exclusion criteria
* Patients epileptic autistics treated by anticomitiaux or having hurts of the central nervous system * Patients autistics receiving a psychotropic treatment * Patients presenting disorders electrolytes * Patients presenting a hypersensibility known about sulpha drugs * Presenting patients against indications relative to the treatment by bumetanide * Patients already treated by diuretics * Patients presenting a hepatic or renal incapacity * Patients presenting an elongation of the QT to the electrocardiogram. * Patients autistics of CARS sore is lower than 30.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Child Autism Rating Scale score | day 0 to day 90 |
Secondary
| Measure | Time frame |
|---|---|
| Clinical global impressions score | day 0 to day 90 |
| Repetitive end restricted behavior score | day 0 to day 90 |
| GRAM score | day 0 to day 90 |
Countries
France
Outcome results
None listed